Tue Aug 30, 2011 7:02am EDT
* Co says may need to do additional trials
* FDA raises issues related to manufacturing, safety
Aug 30 (Reuters) - NuPathe Inc said the U.S. health regulator rejected its experimental migraine patch and the company may need to conduct additional trials to address the issues raised by regulators.
In a complete response letter to the company, the U.S. Food and Drug Administration raised questions related to the chemistry, manufacturing and safety of the treatment, known as Zelrix, the company said in a statement.
NuPathe believes it has, or shortly will have, sufficient data to address the issues and may conduct additional early-stage and/or non-clinical studies to address other questions.
The company will also request a meeting with the FDA to discuss the letter and its approach to resolve the issues.
Migraine is a neurological disorder that affects about 30 million adults in the United States, NuPathe said.
Shares of the company closed at $4.05 on Monday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)
Recent PATH News
- UiPath Unveils New Family of LLMs at AI Summit to Empower Enterprises to Harness Full Capabilities of GenAI • Business Wire • 03/19/2024 12:00:00 PM
- Fisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase Initiative • IH Market News • 03/14/2024 11:39:32 AM
- UiPath Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results • Business Wire • 03/13/2024 08:10:00 PM
- Mixed Futures Amidst Quiet Economic Schedule; Oil Prices Climb • IH Market News • 03/13/2024 11:03:39 AM
- Saudi Arabia Ministry of Tourism Boosts Vision for Excellence and Sustainable Growth with UiPath AI and Automation • Business Wire • 03/06/2024 01:05:00 PM
- UiPath Announces Investments in Saudi Arabia, Including First Saudi School of Automation and New Office Location in Riyadh • Business Wire • 03/04/2024 08:00:00 AM
- UiPath and Google Cloud Expand Strategic Partnership to Accelerate Access to Gen AI and Cloud-based Automation • Business Wire • 02/29/2024 01:00:00 PM
- UiPath to Exhibit AI-powered Automation Solutions for Healthcare Industry at ViVE 2024 Conference • Business Wire • 02/22/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 01:03:36 AM
- UiPath Announces New Developer Features at DevCon 2024 to Bring Latest in AI-powered Productivity to Developer Community • Business Wire • 02/16/2024 03:30:00 AM
- UiPath and Deloitte Collaborate to Introduce Turnkey Automation Offering for Growth Companies • PR Newswire (US) • 02/15/2024 09:30:00 PM
- UiPath Announces Fourth Quarter and Full Year Fiscal 2024 Financial Results Conference Call • Business Wire • 02/14/2024 09:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 10:25:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 10:33:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 10:31:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:13:44 PM
- Deloitte and UiPath Expand Strategic Alliance With New SAP Delivery Framework to Accelerate Clients' Business Transformation • PR Newswire (US) • 01/24/2024 01:45:00 PM
- UiPath Expands Customer Leadership with Appointment of Pradeep Kumar as Senior Vice President of Services and Customer Success • Business Wire • 01/22/2024 01:00:00 PM
- UiPath to Participate in the 26th Annual Needham Growth Conference • Business Wire • 01/12/2024 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:15:58 PM
- UiPath Appoints Co-CEO Rob Enslin and Veteran Technology Executive June Yang to its Board of Directors • Business Wire • 01/10/2024 09:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:17:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/08/2024 09:14:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/04/2024 09:17:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/04/2024 09:16:59 PM
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • HLYK • Mar 19, 2024 8:00 AM
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • ELAB • Mar 18, 2024 8:51 AM
Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • PEI • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM